RedHill Biopharma: Up on safety panel nod to continue COVID-19 treatment study

Redhill Biopharma

19/11/2020 12:33

** Israeli drugmaker's U.S.-listed shares  RDHL.O  rise
17.7% to $9.3 premarket; Set for their best session in 8 months 
    ** Co says it has received an unanimous recommendation from
an independent Data and Safety Monitoring Board to continue its
global mid-to-late-stage study to treat hospitalized patients
with severe COVID-19 pneumonia  urn:newsml:reuters.com:*:nPn2Yszs7a
    ** The board's decision is based on an unblinded analysis of
safety data from the first 70 patients treated for 14 days -
RDHL
    ** Co plans to apply for emergency use applications in Q1 of
2021
    ** The study is being conducted in 6 countries and RDHL
expects to enroll 270 patients 
    ** Up to Wednesday's close, stock had risen ~30% YTD

 (Reporting by Dania Nadeem in Bengaluru)
 ((Dania.Nadeem@thomsonreuters.com;))